MCID: NRL005
MIFTS: 61

Neurilemmoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neurilemmoma

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 12 50 56 42 14 69
Schwannoma 12 50 29 52
Benign Schwannoma 50 56 69
Peripheral Fibroblastoma 50 56
Neurilemoma 50 56
Psammomatous Schwannoma 12
Neurolemmoma 50

Characteristics:

Orphanet epidemiological data:

56
benign schwannoma
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 56  
Rare neurological diseases


Summaries for Neurilemmoma

NIH Rare Diseases : 50 a schwannoma is a tumor of the peripheral nervous system that arises in the nerve sheath (tissue that protects the nerves). it develops from a type of cell called a schwann cell, giving the tumor its name. it is almost always benign (not cancerous), but rare malignant schwannomas have been reported. although schwannomas can arise from any nerve in the body, the most common locations include the head, arms, legs and trunk. the presence of a schwannoma may first become apparent with a cosmetic deformity, a noticeable mass, symptoms similar to a compressive neuropathy (pinched nerve), or some combination of these. neurologic symptoms tend to occur later. symptoms can be vague, and it may be several years before the tumor is diagnosed. the cause of schwannomas is not known. in some cases they are associated with neurofibromatosis. in these cases, multiple tumors may be present. treatment of benign schwannomas involves surgery to remove the tumor, which usually results in complete and fast relief of symptoms. treatment of malignant schwannomas may involve surgery, radiation therapy, and/or chemotherapy. last updated: 6/14/2017

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to macrocystic neurilemmoma and mediastinal neurilemmoma, and has symptoms including vertigo, facial palsy and nasal polyposis. An important gene associated with Neurilemmoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are ERK Signaling and Cytoskeletal Signaling. The drugs Anti-Bacterial Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone and breast, and related phenotypes are Decreased viability and behavior/neurological

Wikipedia : 72 A schwannoma is a benign nerve sheath tumor composed of Schwann cells, which normally produce the... more...

Related Diseases for Neurilemmoma

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
id Related Disease Score Top Affiliating Genes
1 macrocystic neurilemmoma 33.5 GFAP NF2 SMARCB1
2 mediastinal neurilemmoma 11.8
3 sympathetic neurilemmoma 11.8
4 melanotic neurilemmoma 11.8
5 neurilemmoma of the fifth cranial nerve 11.7
6 mediastinal melanocytic neurilemmoma 11.7
7 neurilemmoma of the pleura 11.7
8 benign dermal neurilemmoma 11.7
9 benign mediastinal psammomatous neurilemmoma 11.7
10 benign mediastinal neurilemmoma 11.7
11 schwannomatosis 11.5
12 cellular schwannoma 11.2
13 acoustic neuroma 11.0
14 plexiform schwannoma 11.0
15 malignant peripheral nerve sheath tumor 10.9
16 neurofibromatosis-noonan syndrome 10.9 NF1 NF2
17 distal trisomy 6q 10.9 NF2 SMARCB1
18 brain stem astrocytic neoplasm 10.8 GFAP NF1
19 renal pelvis urothelial papilloma 10.8 GFAP NF2
20 verruciform xanthoma of skin 10.8 ENO2 NF2
21 anovulation 10.8 GFAP NF2
22 anus leiomyoma 10.8 GFAP KIT
23 posterior urethra cancer 10.8 ENO2 SMARCB1
24 gallbladder papillary carcinoma 10.7 ENO2 NF2
25 glomus tumor 10.7 ENO2 KIT
26 schwannoma of jugular foramen 10.7
27 cervical keratinizing squamous cell carcinoma 10.7 ENO2 NF1
28 invasive malignant thymoma 10.7 KIT S100B
29 ovarian mucinous cystadenofibroma 10.7 GFAP S100B
30 motor neuron disease 10.6 ENO2 S100B
31 reactive arthritis 10.6 EZR GFAP
32 functional colonic disease 10.6 GFAP SMARCB1
33 diphtheria 10.6 ENO2 NF1 NF2
34 clear cell ependymoma 10.6 GFAP NF1 NF2
35 vulvar benign neoplasm 10.6 ENO2 GFAP
36 lung benign neoplasm 10.6 ENO2 SMARCB1
37 lymphoplasmacytic lymphoma 10.6 NF1 NF2 PRKAR1A
38 epidural abscess 10.6 ENO2 NF1 NF2
39 pleural empyema 10.6 GFAP NF2 S100B
40 cauda equina intradural extramedullary astrocytoma 10.6 ENO2 GFAP
41 postmenopausal atrophic vaginitis 10.6 ENO2 NF1 NF2
42 cauda equina neoplasm 10.6 ENO2 GFAP NF2
43 gastric papillary adenocarcinoma 10.6 KIT S100B
44 third cranial nerve disease 10.6 GFAP NF2
45 movement disease 10.6 KIT PDGFRA
46 mediastinal granular cell myoblastoma 10.6 ENO2 SOX10
47 marfanoid habitus-inguinal hernia-advanced bone age syndrome 10.6 DES KIT
48 nodular medulloblastoma 10.6 ENO2 GFAP SMARCB1
49 childhood choroid plexus cancer 10.5 ENO2 GFAP SMARCB1
50 brachial plexus neuritis 10.5 ENO2 GFAP SMARCB1

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma

Symptoms & Phenotypes for Neurilemmoma

Human phenotypes related to Neurilemmoma:

56 32 (show all 27)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vertigo 56 32 frequent (33%) Frequent (79-30%) HP:0002321
2 facial palsy 56 32 frequent (33%) Frequent (79-30%) HP:0010628
3 nasal polyposis 56 32 occasional (7.5%) Occasional (29-5%) HP:0100582
4 vestibular schwannoma 56 32 hallmark (90%) Very frequent (99-80%) HP:0009588
5 acute episodes of neuropathic symptoms 56 32 occasional (7.5%) Occasional (29-5%) HP:0003489
6 hearing abnormality 56 32 frequent (33%) Frequent (79-30%) HP:0000364
7 morphological abnormality of the central nervous system 56 32 occasional (7.5%) Occasional (29-5%) HP:0002011
8 intestinal polyposis 56 32 occasional (7.5%) Occasional (29-5%) HP:0200008
9 abnormality of the liver 56 32 occasional (7.5%) Occasional (29-5%) HP:0001392
10 abnormality of the adrenal glands 56 32 occasional (7.5%) Occasional (29-5%) HP:0000834
11 abnormality of the larynx 56 32 occasional (7.5%) Occasional (29-5%) HP:0001600
12 abnormality of parotid gland 56 32 occasional (7.5%) Occasional (29-5%) HP:0000197
13 abnormality of the breast 56 32 occasional (7.5%) Occasional (29-5%) HP:0000769
14 peripheral schwannoma 56 32 hallmark (90%) Very frequent (99-80%) HP:0009593
15 abnormality of the temporal bone 56 32 hallmark (90%) Very frequent (99-80%) HP:0009911
16 abnormality of the twelfth cranial nerve 56 32 occasional (7.5%) Occasional (29-5%) HP:0010826
17 abnormality of peripheral nervous system electrophysiology 56 32 hallmark (90%) Very frequent (99-80%) HP:0030177
18 allodynia 56 32 frequent (33%) Frequent (79-30%) HP:0012533
19 scleral schwannoma 56 32 hallmark (90%) Very frequent (99-80%) HP:0100011
20 pain 56 Occasional (29-5%)
21 neurofibrosarcoma 56 Excluded (0%)
22 schwannoma 56 Very frequent (99-80%)
23 abnormality of the cranial nerves 56 Very frequent (99-80%)
24 abnormality of the fibula 56 Occasional (29-5%)
25 abnormality of the esophagus 56 Occasional (29-5%)
26 abnormality of esophagus morphology 32 occasional (7.5%) HP:0002031
27 abnormality of fibula morphology 32 occasional (7.5%) HP:0002991

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.33 PDGFRA
2 Decreased viability GR00221-A-1 10.33 SMARCB1 KIT NF1 PDGFRA PRKAR1A
3 Decreased viability GR00221-A-2 10.33 SMARCB1 NF1 PRKAR1A
4 Decreased viability GR00221-A-3 10.33 SMARCB1 PDGFRA PRKAR1A NF2
5 Decreased viability GR00221-A-4 10.33 NF1 PDGFRA PRKAR1A
6 Decreased viability GR00301-A 10.33 KIT
7 Decreased viability GR00381-A-1 10.33 SMARCB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 S100B SMARCB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 SOX10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.9 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.9 SMARCB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.9 SOX10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 SMARCB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.9 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.9 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.9 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.9 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.9 VIM SMARCB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.9 VIM SOX10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.9 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.9 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.9 SMARCB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.9 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.9 KIT VIM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.9 SOX10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.9 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.9 SOX10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.9 VIM S100B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 SOX10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.9 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.9 SMARCB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.9 KIT VIM S100B SMARCB1 SOX10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.9 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.9 KIT
37 Increased proliferation GR00094-A 8.96 NF2 SMARCB1

MGI Mouse Phenotypes related to Neurilemmoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 DES ENO2 GFAP KIT NF1 NF2
2 cellular MP:0005384 10.3 DES ENO2 GFAP KIT NF1 NGFR
3 homeostasis/metabolism MP:0005376 10.27 NF1 NF2 NGFR PDGFRA PRKAR1A S100B
4 growth/size/body region MP:0005378 10.25 ENO2 EZR GFAP KIT NF1 NF2
5 cardiovascular system MP:0005385 10.22 DES GFAP KIT NF1 NGFR PDGFRA
6 mortality/aging MP:0010768 10.21 VIM DES EZR GFAP KIT NF1
7 digestive/alimentary MP:0005381 10.19 EZR GFAP KIT NF1 NGFR PDGFRA
8 immune system MP:0005387 10.18 EZR GFAP KIT NF1 NF2 NGFR
9 embryo MP:0005380 10.13 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
10 craniofacial MP:0005382 10.09 ENO2 KIT NF1 NF2 NGFR PDGFRA
11 muscle MP:0005369 10.06 DES GFAP KIT NF1 NGFR PDGFRA
12 nervous system MP:0003631 10.02 ENO2 GFAP KIT NF1 NF2 NGFR
13 integument MP:0010771 10 NF1 NF2 NGFR PDGFRA S100B SOX10
14 neoplasm MP:0002006 9.91 KIT NF1 NF2 PDGFRA PRKAR1A SMARCB1
15 normal MP:0002873 9.91 MSN NF1 NGFR PDGFRA PRKAR1A S100B
16 respiratory system MP:0005388 9.61 ENO2 KIT NF1 NF2 NGFR PDGFRA
17 pigmentation MP:0001186 9.55 PRKAR1A SOX10 KIT NF1 PDGFRA
18 vision/eye MP:0005391 9.23 GFAP KIT NF1 NF2 NGFR PRKAR1A

Drugs & Therapeutics for Neurilemmoma

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
3 Gentamicins Phase 4
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
8
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
9
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
10
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
11 Protein Kinase Inhibitors Phase 2, Phase 3,Early Phase 1
12 Antiemetics Phase 3
13 Anti-Inflammatory Agents Phase 3,Phase 2
14 Antineoplastic Agents, Hormonal Phase 3
15 Autonomic Agents Phase 3
16 Gastrointestinal Agents Phase 3
17 glucocorticoids Phase 3
18 Hormone Antagonists Phase 3
19 Hormones Phase 3
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
21 Methylprednisolone acetate Phase 3
22 Methylprednisolone Hemisuccinate Phase 3
23 Neuroprotective Agents Phase 3
24 Peripheral Nervous System Agents Phase 3,Phase 2
25 Prednisolone acetate Phase 3
26 Prednisolone hemisuccinate Phase 3
27 Prednisolone phosphate Phase 3
28 Protective Agents Phase 3,Phase 2
29 Alkylating Agents Phase 3,Phase 2,Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
31 Isophosphamide mustard Phase 3,Phase 2
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Imatinib Mesylate Phase 2, Phase 3 123596
34
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
35
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
36
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
38
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
39
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
40
Etoposide Approved Phase 2 33419-42-0 36462
41
Lenograstim Approved Phase 2 135968-09-1
42
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
43
Pembrolizumab Approved Phase 2 1374853-91-4
44
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
45
nivolumab Approved Phase 2 946414-94-4
46
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
47
Xylometazoline Approved Phase 1, Phase 2 526-36-3 5709
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 93)

id Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Enrolling by invitation NCT02884154 Phase 4
4 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
5 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3 methylprednisolone
6 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
10 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
11 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
12 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
13 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
14 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
15 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
16 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
17 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
18 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
19 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
20 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
21 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
22 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Recruiting NCT01345136 Phase 2 RAD001, everolimus
23 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
24 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
25 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
26 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
27 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
28 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
29 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
32 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
33 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
34 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
35 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
36 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
37 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
38 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2 Alisertib
39 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
40 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
41 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2 Aspirin;Placebo
42 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT02986919 Phase 2 CPI-0610
43 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Suspended NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
44 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2 PTC299
45 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
46 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
47 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Gemcitabine and Docetaxel in Combination with Pazopanib
48 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
49 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
50 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Genetic Tests for Neurilemmoma

Genetic tests related to Neurilemmoma:

id Genetic test Affiliating Genes
1 Schwannoma 29

Anatomical Context for Neurilemmoma

MalaCards organs/tissues related to Neurilemmoma:

39
Tongue, Bone, Breast, Brain, Thyroid, Liver, Adrenal Gland

Publications for Neurilemmoma

Articles related to Neurilemmoma:

(show top 50) (show all 455)
id Title Authors Year
1
Surgical management of a large neurilemmoma-like leiomyoma of the uterine cervix mimicking a retroperitoneal tumor. ( 28702500 )
2017
2
Intraoral neurilemmoma of mental nerve mimicking as traumatic fibroma: An unusual presentation - A case report and literature review. ( 28479699 )
2017
3
Laparoscopic resection of retroperitoneal benign neurilemmoma. ( 28289669 )
2017
4
Erratum: Affiliation and corresponding author correction: Laparoscopic resection of retroperitoneal benign neurilemmoma. ( 28480189 )
2017
5
Neurilemmoma in the floor of the mouth: a case report. ( 26904498 )
2016
6
Neurilemmoma of the Vagus Nerve in the Poststyloid Parapharyngeal Space. ( 26894190 )
2016
7
Schwannoma (Neurilemmoma) on the Base of the Tongue: A Rare Clinical Case. ( 27018477 )
2016
8
Recurrent Ancient Intraosseous Neurilemmoma of Maxilla: A Rare Case Report. ( 27499782 )
2016
9
Intraventricular Neurilemmoma (Schwannoma): Shall GFAP Immunostaining Be Regarded as a Histogenetical Tag or as a Mere Histomimetical Trait? ( 27446622 )
2016
10
Neurilemmoma Of External Ear, Confirmed By Immunohistochemistry-A Telepathological Communication Between Cyprus And India. ( 28828767 )
2016
11
Cervical vagus nerve neurilemmoma mimicking parathyroid adenoma. ( 27562903 )
2016
12
Benign paravertebral ancient neurilemmoma in a young adult: a rare occurrence. ( 25738029 )
2015
13
Vaginal Neurilemmoma: Case Report with Brief Review. ( 27217689 )
2015
14
Neurilemmoma of Deep Peroneal Nerve Sensory Branch : Thermographic Findings with Compression Test. ( 26539275 )
2015
15
Surgical outcome of spinal neurilemmoma: two case reports. ( 25654395 )
2015
16
Thoracic Neurilemmoma Presenting With Spinal Nerve Involvement in Promyelocytic Leukemia. ( 25950139 )
2015
17
Neurilemmoma of Retromolar Region in the Oral Cavity. ( 26221545 )
2015
18
Primary Neurilemmoma of the Thyroid Gland Clinically Mimicking Malignant Thyroid Nodule. ( 26498011 )
2015
19
Neurilemmoma of median nerve. ( 25983466 )
2014
20
Neurilemmoma of lateral nasal wall. ( 25179720 )
2014
21
Intraosseous neurilemmoma of the proximal ulna. ( 25460435 )
2014
22
Intestinal neurilemmoma. ( 24157416 )
2014
23
Penile neurilemmoma: Utility of fine-needle aspiration cytology in diagnosis of a rare entity. ( 25538392 )
2014
24
Maxillary neurilemmoma-Rarest of the rare tumour: Report of 2 cases. ( 24129122 )
2013
25
Neurilemmoma Showing a Unique Growth Pattern in the Lateral Chest Wall: Both Inside and Outside the Thoracic Cavity. ( 23445787 )
2013
26
Lateral cervical approach combined with posterior thoracotomy for the treatment of giant neurilemmoma of the chest involving the neck. ( 22884113 )
2013
27
Ancient neurilemmoma: A rare oral tumor. ( 24574671 )
2013
28
Laparoscopic phrenectomy for a diaphragmatic neurilemmoma. ( 24250705 )
2013
29
Human pulmonary dirofilariasis coexisting with intercostal neurilemmoma: a case report and literature review. ( 24080016 )
2013
30
Rectal schwannoma (neurilemmoma). ( 22369805 )
2012
31
Hibernoma in the thoracic back muscle accompanied by neurilemmoma. ( 25983847 )
2012
32
Value of ultrasonography in neurilemmoma diagnosis: the role of round shape morphology. ( 22957323 )
2012
33
Giant neurilemmoma of the vagus nerve: a case report and review of literature. ( 23936960 )
2012
34
Multiple neurilemmomas in Birt-Hogg-DubAc syndrome: case report. ( 22326190 )
2012
35
Neurilemmoma of the thyroid gland. ( 22728508 )
2012
36
Mesentery neurilemmoma: CT, MRI and angiographic findings. ( 22041360 )
2011
37
Lower neck neurilemmoma can masquerade as lymph node metastasis on FDG PET/CT in patient with nasopharyngeal carcinoma. ( 22064115 )
2011
38
Intraosseous neurilemmoma of the mandible: report of a rare ancient type. ( 22013479 )
2011
39
Dermal schwannoma (neurilemmoma): a peculiar foreign body reaction? ( 20216197 )
2010
40
Neurilemmoma (schwannoma) of the thyroid gland: a rare case presentation. ( 21045459 )
2010
41
Neurilemmoma presenting as a midline nasal mass in a pediatric patient. ( 20461682 )
2010
42
Intranodal neurilemmoma presenting as parotid mass. ( 18940018 )
2009
43
Neurilemmoma of the first branch of the lateral plantar nerve causing tarsal tunnel syndrome. ( 20400427 )
2009
44
Mandible schwannoma (neurilemmoma) presenting as periapical lesion. ( 19225090 )
2009
45
Wagner-Meissner neurilemmoma of the right cheek. ( 18486897 )
2008
46
Fibroadenoma with digital fibroma-like inclusions in neurilemmoma-like stromal component. ( 18186878 )
2008
47
Multinodular neurilemmoma of the tongue: a case report with differential immunohistochemical profile. ( 18427374 )
2008
48
Retroperitoneal neurilemmoma (schwannoma). ( 17635295 )
2007
49
Neurilemmoma of the abdomen. ( 17699937 )
2007
50
Two cases of neurilemmoma of the tongue. ( 18225629 )
2007

Variations for Neurilemmoma

Copy number variations for Neurilemmoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplific ation SMARCB1 Schwannoma

Expression for Neurilemmoma

Search GEO for disease gene expression data for Neurilemmoma.

Pathways for Neurilemmoma

GO Terms for Neurilemmoma

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 apical part of cell GO:0045177 9.65 EZR MSN NF2
2 ruffle GO:0001726 9.63 EZR NF2 S100B
3 filopodium GO:0030175 9.5 EZR MSN NF2
4 plasma membrane raft GO:0044853 9.49 EZR PRKAR1A
5 cytoplasm GO:0005737 9.47 DES ENO2 EZR GFAP KIT MSN
6 intermediate filament GO:0005882 9.46 DES GFAP NES VIM
7 uropod GO:0001931 9.43 EZR MSN
8 microvillus GO:0005902 9.43 EZR MSN PDGFRA
9 cell body GO:0044297 9.4 EZR NF2
10 intermediate filament cytoskeleton GO:0045111 9.13 DES GFAP NES
11 astrocyte projection GO:0097449 9.07 EZR

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.76 NF1 NF2 PRKAR1A
2 phosphatidylinositol-mediated signaling GO:0048015 9.73 EZR KIT PDGFRA
3 positive regulation of gene expression GO:0010628 9.62 EZR KIT MSN VIM
4 negative regulation of cell-matrix adhesion GO:0001953 9.57 NF1 NF2
5 establishment of endothelial barrier GO:0061028 9.55 EZR MSN
6 establishment of epithelial cell apical/basal polarity GO:0045198 9.54 EZR MSN
7 positive regulation of cellular protein catabolic process GO:1903364 9.52 EZR MSN
8 positive regulation of phospholipase C activity GO:0010863 9.51 KIT PDGFRA
9 gland morphogenesis GO:0022612 9.49 EZR MSN
10 positive regulation of early endosome to late endosome transport GO:2000643 9.46 EZR MSN
11 regulation of cell shape GO:0008360 9.46 EZR KIT MSN S100B
12 negative regulation of neuron projection development GO:0010977 9.43 NGFR VIM
13 positive regulation of protein localization to early endosome GO:1902966 9.4 EZR MSN
14 membrane to membrane docking GO:0022614 9.37 EZR MSN
15 astrocyte development GO:0014002 9.27 VIM
16 regulation of organelle assembly GO:1902115 9.26 EZR MSN
17 Bergmann glial cell differentiation GO:0060020 9.18 VIM
18 intermediate filament-based process GO:0045103 8.65 VIM
19 intermediate filament organization GO:0045109 8.62 DES VIM

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.65 DES GFAP S100B SOX10 VIM
2 protein kinase A catalytic subunit binding GO:0034236 9.37 EZR PRKAR1A
3 S100 protein binding GO:0044548 9.32 EZR S100B
4 structural constituent of cytoskeleton GO:0005200 9.26 DES GFAP MSN VIM
5 cytoskeletal protein binding GO:0008092 8.92 DES EZR MSN NF2
6 protein binding GO:0005515 10.03 DES ENO2 EZR GFAP KIT MSN

Sources for Neurilemmoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....